Opinion|Videos|September 5, 2024

Advanced Treatment Options for RA: Exploring the Data

Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).

Episodes in this series

Video content above is prompted by the following:

Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.

  • Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab.
  • Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).
  • What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?

Related Content